On July 23, 2026 AnHorn Medicines reported the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotective candidate being developed to prevent chemotherapy-induced peripheral neuropathy (CIPN). This milestone marks the clinical advancement of a novel therapeutic approach designed to address one of the most common and debilitating complications of cancer treatment.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Addressing a Significant Unmet Medical Need
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting side effect of widely used cancer therapies, including taxanes, platinum-based agents, vinca alkaloids, and antibody-drug conjugates (ADCs). CIPN can cause numbness, tingling, pain, and sensory impairment that often persist long after treatment ends.

Studies indicate that 60–70% of patients experience CIPN during or shortly after chemotherapy, and nearly one-third continue to suffer six months or longer post-treatment. Despite its substantial burden, no approved therapies currently exist to prevent CIPN, and treatment options for established neuropathy remain limited.[1]

Preventing CIPN: Benefits for Patients and Cancer Care
CIPN not only impacts patient quality of life but also forces oncologists to reduce chemotherapy doses, delay schedules, or discontinue therapy—compromising treatment outcomes.

By preventing nerve damage before it occurs, AH-008 has the potential to:

Improve quality of life for patients undergoing chemotherapy
Reduce treatment-related pain, numbness, and sensory dysfunction
Preserve chemotherapy dose intensity and adherence
Enable patients to remain on optimal anti-cancer regimens
Reduce long-term healthcare costs associated with chronic neuropathy
"The economic burden of CIPN is estimated at approximately $17,000 per patient, translating into a total societal burden of up to $153 billion. Preventing CIPN represents one of the most significant unmet needs in supportive oncology today," said Shu-Jen Chen, Chief Scientific Officer of AnHorn Medicines. "The successful first patient dosing in our Phase I study marks an important step toward developing a disease-modifying therapy that could protect patients from debilitating nerve damage while enabling them to receive the full benefit of cancer treatment."

Large and Growing Market Opportunity
Each year, millions of cancer patients worldwide receive neurotoxic chemotherapy agents associated with CIPN. As these regimens expand across global markets, CIPN remains one of the most common and clinically meaningful dose-limiting toxicities in oncology.

With no approved preventive therapies, the global addressable market for CIPN prevention is estimated at US$15-19 billion annually, underscoring the significant commercial opportunity for a first-in-class approach.[2]

The treatment-enabling paradigm of AH-008 is analogous to granulocyte colony-stimulating factors (G-CSF), such as Neulasta, which prevent chemotherapy-induced neutropenia and enable full-dose chemotherapy. Similarly, AH-008 may establish a new standard of care in supportive oncology by addressing a key toxicity that currently limits cancer treatment delivery.

AH-008 Highlights
AH-008 is a novel neuroprotective drug candidate designed to prevent chemotherapy-induced nerve damage before irreversible neuropathy develops.

Key differentiators include:

First-in-class mechanism targeting pathways of chemotherapy-induced neuroinflammation
Preventive approach focused on reducing CIPN incidence
Broad applicability across multiple chemotherapy classes, including taxanes, platinum compounds, and ADCs
Potential to preserve chemotherapy intensity without compromising efficacy
Address a major unmet need with no approved preventive therapies
Strong commercial potential in the growing supportive oncology market
About the AH-008 Phase I Study
The Phase I clinical trial is designed to evaluate the safety, tolerability, and pharmacokinetics of AH-008 in healthy volunteers. The data generated will support subsequent clinical development in cancer patients at risk of developing CIPN.

(Press release, AnHorn Medicines, JUL 23, 2026, View Source [SID1234669389])